Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy

  • Bladder Cancer — Immunotherapies for Bladder Cancer: Sequencing Treatment to Maximize Clinical Benefit – @Point of Care Chapter
  • Immunotherapy has revolutionized bladder cancer management and should be incorporated into the care of patients with metastatic disease as either first-line or second-line therapy. Five immunotherapies that target the programmed cell death protein 1 and programmed death ligand 1 pathway are available and are ... more >>
  • Bladder Cancer — Case Study: Enrollment of a Patient With Metastatic Bladder Cancer in a Combination Immunotherapy Clinical Trial – @Point of Care Chapter
  • Patients with metastatic bladder cancer often progress following first-line systemic therapy. Immune checkpoint inhibitors (ICIs) are an established, FDA-approved second-line treatment option for patients who progress on or after platinum-based chemotherapy. These agents have shown good objective response ... more >>
  • Bladder Cancer — Case Study: Management of a Patient With Metastatic Bladder Cancer and Disease Progression After First-line Treatment – @Point of Care Chapter
  • Bladder cancer is a common malignancy that is strongly associated with smoking history and most often arises from the urothelium. Although second-line treatment options for patients with metastatic urothelial cancer were once limited, the recent approval of several immunotherapies has revolutionized treatment ... more >>
  • Prostate Cancer — Treatment Sequencing to Maximize Outcomes: Clinical Considerations and Implications – Webcast
  • Loss of PTEN leading to activation of the Akt pathway is a common alteration in metastatic castration-resistant prostate cancer (mCRPC) that has important prognostic implications. Until recently, there were no targeted agents for this pathway, but inhibitors of Akt are now in development and late-stage ... more >>
    M. Hussain, Md, FACP, FASCO
  • Prostate Cancer — Identifying Patient Candidates for Akt Inhibitors: Pathologic and Genomic Determinants for Guiding Treatment Choice – Webcast
  • Loss of PTEN leading to activation of the Akt pathway is a common alteration in metastatic castration-resistant prostate cancer that has important prognostic implications. Until recently, there were no targeted agents for this pathway, but inhibitors of Akt are now in development and late-stage clinical ... more >>
    M. Hussain, Md, FACP, FASCO
  • Prostate Cancer — Emerging Targeted Therapies in mCRPC: Focus on the PI3K/Akt/mTOR Pathway – Webcast
  • Over 90% of metastatic castration-resistant prostate cancers (mCRPC) harbor clinically actionable mutations, and one of the most common is loss of PTEN leading to activation of the Akt pathway. This loss has important prognostic implications because it is associated with worse response to treatment, relapse, ... more >>
  • Prostate Cancer — TRITON2 Safety and Efficacy Findings Confirm PARP Benefit in mCRPC – BreakingMED
  • The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib achieved an objective response rate of 43.5% in men with metastatic castration-resistant prostate cancer (mCRPC) who had a BRCA alteration with measurable disease and an ORR of 50.8% in men with BRCA alteration and no measurable disease, according to ... more >>
  • Prostate Cancer — Case Study: Management of Nonmetastatic Castration-Resistant Prostate Cancer – @Point of Care Chapter
  • Localized prostate cancer can often be cured through surgery and/or radiation therapy. In cases of recurrence, androgen-deprivation therapy (ADT) is usually successful, leading to disease regression and prostate-specific antigen (PSA) suppression. However, prostate cancer may progress while on ADT despite ... more >>
    B. Gartrell, MD
  • Prostate Cancer — Men With Localized Prostate Cancer Will Opt for Better QoL over Longer Life – BreakingMED
  • Patients with localized prostate cancer appear to place more value on quality of life issues such as sexual and urinary function than extending survival, according to findings from a discrete choice experiment (DCE) conducted at 34 urology departments.
  • Bladder Cancer — Novel and Evolving Immunotherapeutic Approaches for the Treatment of Bladder Cancer – @Point of Care Chapter
  • This activity focuses on emerging treatment options for metastatic bladder cancer. Current standard therapy is briefly introduced, followed by more detailed discussions of the rationale for immunotherapy development, approved immunotherapy options in advanced bladder cancer, and novel therapies or treatment ... more >>
    J. Weber, MD, PhD
  • Clinical Context: Prostate Cancer
  • Clinical Context: Prostate Cancer is designed to provide up-to-date information on current and emerging management strategies based on the most up-to-date evidence-based medicine and clinical trial results in prostate cancer. The curriculum includes case studies at the point of care and MedPage Today meeting ... more >>
    A. Alva, MD, MBBS
  • Prostate Cancer @Point of Care
  • In this subchapter, treatment of castration-resistant prostate cancer (CRPC) and resistance to the application of androgen deprivation therapy will be discussed. Links to guidelines and clinical studies throughout this chapter will increase the understanding of the approved and emerging agents for CRPC and ... more >>
    E. Crawford, MD
  • Prostate Cancer — Treatment Sequencing to Maximize Outcomes: Clinical Considerations and Implications – Webcast
  • Loss of PTEN leading to activation of the Akt pathway is a common alteration in metastatic castration-resistant prostate cancer (mCRPC) that has important prognostic implications. Until recently, there were no targeted agents for this pathway, but inhibitors of Akt are now in development and late-stage ... more >>
    M. Hussain, Md, FACP, FASCO
  • Prostate Cancer — Identifying Patient Candidates for Akt Inhibitors: Pathologic and Genomic Determinants for Guiding Treatment Choice – Webcast
  • Loss of PTEN leading to activation of the Akt pathway is a common alteration in metastatic castration-resistant prostate cancer that has important prognostic implications. Until recently, there were no targeted agents for this pathway, but inhibitors of Akt are now in development and late-stage clinical ... more >>
    M. Hussain, Md, FACP, FASCO
  • Prostate Cancer — Emerging Targeted Therapies in mCRPC: Focus on the PI3K/Akt/mTOR Pathway – Webcast
  • Over 90% of metastatic castration-resistant prostate cancers (mCRPC) harbor clinically actionable mutations, and one of the most common is loss of PTEN leading to activation of the Akt pathway. This loss has important prognostic implications because it is associated with worse response to treatment, relapse, ... more >>
  • Prostate Cancer — Progressive Metastatic Castrate-Resistant Prostate Cancer – Case Study
  • While prostate cancer is often curable with local treatment, many patients will develop recurrence with metastatic castration-resistant prostate cancer (mCRPC). Several targeted treatments are available for mCRPC, and enrollment into clinical trials plays an important role in management of recurrent disease ... more >>
    T. Dorff, MD
  • Prostate Cancer — Newly Diagnosed Metastatic Prostate Cancer Patient – Case Study
  • This activity reviews a real-life case scenario of a patient with newly diagnosed metastatic hormone-sensitive prostate cancer who was found to have bone metastases. The case reviews available treatment options and highlights the importance of choosing a treatment option based on available clinical data and ... more >>
    N. Agarwal, MD
  • Prostate Cancer — Castration-Resistant Prostate Cancer Patient with Bone Metastases – Case Study
  • This case reviews a real-life case scenario of a patient with castration-resistant prostate cancer who is experiencing bone pain associated with his bone metastases. The case reviews available treatment options and highlights the importance of choosing a treatment based on efficacy and safety of available ... more >>
    A. Alva, MD, MBBS

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information